keyword
MENU ▼
Read by QxMD icon Read
search

transdermal estrogen therapy

keyword
https://www.readbyqxmd.com/read/29234814/hormone-therapy-for-the-primary-prevention-of-chronic-conditions-in-postmenopausal-women-us-preventive-services-task-force-recommendation-statement
#1
David C Grossman, Susan J Curry, Douglas K Owens, Michael J Barry, Karina W Davidson, Chyke A Doubeni, John W Epling, Alex R Kemper, Alex H Krist, Ann E Kurth, C Seth Landefeld, Carol M Mangione, Maureen G Phipps, Michael Silverstein, Melissa A Simon, Chien-Wen Tseng
Importance: Menopause occurs at a median age of 51.3 years, and the average US woman who reaches menopause is expected to live another 30 years. The prevalence and incidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and breast cancer, increase with age; however, the excess risk for these conditions that can be attributed to menopause alone is uncertain. Since the publication of findings from the Women's Health Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy has declined...
December 12, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29208690/aortic-hemodynamics-in-postmenopausal-women-following-cessation-of-hormone-therapy
#2
Ronée E Harvey, Maja C Johnson, Sushant M Ranadive, Michael J Joyner, Brian D Lahr, Virginia M Miller, Jill N Barnes
Central (aortic) blood pressure and aortic pulse wave characteristics are measures of cardiovascular health, predictive of cardiovascular mortality. Previous studies have compared aortic hemodynamics in women who do and do not take menopausal hormone therapy, but characteristics of these parameters following cessation of treatment have not been defined. Therefore, the purpose of this study was to define aortic pulse wave characteristics in postmenopausal women with and without a history of menopausal hormone therapy use...
December 2017: Physiological Reports
https://www.readbyqxmd.com/read/29039146/estrogen-based-hormone-therapy-in-women-with-primary-ovarian-insufficiency-a-systematic-review
#3
Nydia Burgos, Dahima Cintron, Paula Latortue-Albino, Valentina Serrano, Rene Rodriguez Gutierrez, Stephanie Faubion, Gabriela Spencer-Bonilla, Patricia J Erwin, Mohammad Hassan Murad
PURPOSE: Sex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI...
December 2017: Endocrine
https://www.readbyqxmd.com/read/28994639/migraine-menopause-and-hormone-replacement-therapy
#4
E Anne MacGregor
Perimenopause marks a period of increased migraine prevalence in women and many women also report troublesome vasomotor symptoms. Migraine is affected by fluctuating estrogen levels with evidence to support estrogen 'withdrawal' as a trigger of menstrual attacks of migraine without aura, while high estrogen levels can trigger migraine aura. Maintaining a stable estrogen environment with estrogen replacement can benefit estrogen-withdrawal migraine particularly in women who would also benefit from relief of vasomotor symptoms...
January 1, 2017: Post Reproductive Health
https://www.readbyqxmd.com/read/28953214/clinical-trials-in-menopause
#5
Kathryn I Marko, James A Simon
OBJECTIVE: Clinical trials in menopause have undergone much scrutiny over the years. This has led to significant shifts in the treatment of symptomatic menopause and a substantial impact on women. We aim to delineate the key studies contributing to this controversy and highlight new directions specifically related to menopausal hormone therapy (HT) and vascular disease risk. METHODS: We performed a search of sentinel studies delineating the risks and benefits of HT in otherwise healthy postmenopausal women...
September 25, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28846767/effects-of-oral-vs-transdermal-estrogen-therapy-on-sexual-function-in-early-postmenopause-ancillary-study-of-the-kronos-early-estrogen-prevention-study-keeps
#6
MULTICENTER STUDY
Hugh S Taylor, Aya Tal, Lubna Pal, Fangyong Li, Dennis M Black, Eliot A Brinton, Matthew J Budoff, Marcelle I Cedars, Wei Du, Howard N Hodis, Rogerio A Lobo, JoAnn E Manson, George R Merriam, Virginia M Miller, Frederick Naftolin, Genevieve Neal-Perry, Nanette F Santoro, Sherman M Harman
Importance: Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition. Objective: To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women. Design, Setting, and Participants: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women...
October 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28832429/effects-of-oral-versus-transdermal-menopausal-hormone-treatments-on-self-reported-sleep-domains-and-their-association-with-vasomotor-symptoms-in-recently-menopausal-women-enrolled-in-the-kronos-early-estrogen-prevention-study-keeps
#7
Dahima Cintron, Brian D Lahr, Kent R Bailey, Nanette Santoro, Robin Lloyd, JoAnn E Manson, Genevieve Neal-Perry, Lubna Pal, Hugh S Taylor, Whitney Wharton, Fredrick Naftolin, S Mitchell Harman, Virginia M Miller
OBJECTIVE: This study determined whether two different formulations of hormone therapy (HT): oral conjugated equine estrogens (o-CEE; 0.45 mg/d, n = 209), transdermal 17β-estradiol (t-E2; 50 μg/d, n = 201) plus cyclic progesterone (Prometrium, 200 mg) or placebo (PBO, n = 243) affected sleep domains in participants of the Kronos Early Estrogen Prevention Study. METHODS: Participants completed the Pittsburgh Sleep Quality Index at baseline and during the intervention at 6, 18, 36, and 48 months...
August 21, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28831686/food-versus-pharmacy-assessment-of-nutritional-and-pharmacological-strategies-to-improve-bone-health-in-energy-deficient-exercising-women
#8
REVIEW
Emily A Southmayd, Adelaide C Hellmers, Mary Jane De Souza
PURPOSE OF REVIEW: The review aims to summarize our current knowledge surrounding treatment strategies aimed at recovery of bone mass in energy-deficient women suffering from the Female Athlete Triad. RECENT FINDINGS: The independent and interactive contributions of energy status versus estrogen status on bone density, geometry, and strength have recently been reported, highlighting the importance of addressing both energy and estrogen in treatment strategies for bone health...
October 2017: Current Osteoporosis Reports
https://www.readbyqxmd.com/read/28816930/associations-among-circulating-csf-1-estrogen-and-bone-mineral-density-in-postmenopausal-women-results-from-a-randomized-placebo-controlled-trial
#9
Andrea V Haas, Elaine Cong, Christine A Simpson, Nitin Sukumar, Yanhong Deng, Karl L Insogna
OBJECTIVE: This study addresses the relationship between circulating levels of colony-stimulating factor 1 (CSF-1) and rates of postmenopausal bone loss. The purpose was to test the hypothesis that CSF-1 levels would correlate with the rate of bone loss in estrogen-deficient woman. We further hypothesized that estrogen replacement would eliminate this association. METHODS: This was an ancillary study to the parent Kronos Early Estrogen Prevention Study (KEEPS)-a 4-year randomized placebo-controlled study that evaluated the effects of estrogen therapy on cardiovascular endpoints...
August 14, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28814476/phase-i-trial-of-the-androgen-receptor-modulator-cr1447-in-breast-cancer-patients
#10
Martin Zweifel, Beat Thürlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa
CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. The objective of this first-in man trial was to evaluate the safety and to determine the dose of CR1447, administered as an ointment, for Phase II. Escalating doses (100, 200, 400 mg) of CR1447 were administered topically on a daily basis to patients with ER-positive/AR-positive/HER2-negative advanced breast cancer pretreated with several lines of therapy...
October 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28738421/cardiovascular-disease-among-transgender-adults-receiving-hormone-therapy-a-narrative-review
#11
REVIEW
Carl G Streed, Omar Harfouch, Francoise Marvel, Roger S Blumenthal, Seth S Martin, Monica Mukherjee
Recent reports estimate that 0.6% of adults in the United States, or approximately 1.4 million persons, identify as transgender. Despite gains in rights and media attention, the reality is that transgender persons experience health disparities, and a dearth of research and evidence-based guidelines remains regarding their specific health needs. The lack of research to characterize cardiovascular disease (CVD) and CVD risk factors in transgender populations receiving cross-sex hormone therapy (CSHT) limits appropriate primary and specialty care...
August 15, 2017: Annals of Internal Medicine
https://www.readbyqxmd.com/read/28697036/comparison-of-clinical-outcomes-among-users-of-oral-and-transdermal-estrogen-therapy-in-the-women-s-health-initiative-observational-study
#12
Carolyn J Crandall, Kathleen M Hovey, Christopher Andrews, Jane A Cauley, Marcia Stefanick, Chrisandra Shufelt, Ross L Prentice, Andrew M Kaunitz, Charles Eaton, Jean Wactawski-Wende, JoAnn E Manson
OBJECTIVE: To examine associations of estrogen preparations with an index of health risks versus benefits. METHODS: Using data from 45,112 participants of the Women's Health Initiative Observational Study (average follow-up 5.5 years), we examined associations of estrogen type and oral conjugated equine estrogen (CEE) dose with time to first global index event (GIE), defined as coronary heart disease, breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death...
October 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28626058/risk-of-stroke-with-various-types-of-menopausal-hormone-therapies-a-national-cohort-study
#13
Ellen Løkkegaard, Lars Hougaard Nielsen, Niels Keiding
BACKGROUND AND PURPOSE: Double-blind randomized studies on the effects of oral postmenopausal hormone therapies were stopped mainly because of increased risk of stroke. We aimed to assess the risk of all strokes and various subtypes associated with hormone therapy and explore the influence of regimens and routes of administration. METHODS: A national historical cohort of women aged 51 to 70 years from 1995 to 2010 was established by linking 5 Danish registries. The National Registry of Medicinal Product Statistics provided information on hormone therapy exposure and the National Patient or Cause of Death Registries supplied data regarding stroke diagnoses (ischemic/hemorrhagic/subarachnoid hemorrhage)...
August 2017: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/28622476/the-effect-of-transdermal-estrogen-patch-use-on-cardiovascular-outcomes-a-systematic-review
#14
Prema Bezwada, Atif Shaikh, Deepika Misra
BACKGROUND: Vasomotor symptoms are the most commonly reported menopausal symptoms. Hormone therapy has been widely used to relieve postmenopausal symptoms. With studies suggesting an increased risk of cardiovascular events and breast cancer with oral hormone therapy use, there has been reluctance to use it. The transdermal estrogen patch provides relief from menopausal symptoms. However, there are limited data on mortality and cardiovascular outcomes, while on the transdermal estrogen patch...
June 16, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28540770/transdermal-estrogens-in-the-changing-landscape-of-hormone-replacement-therapy
#15
REVIEW
Keli L Beck, Michelle C Anderson, Julienne K Kirk
Views and clinical practice on hormone replacement therapy (HRT) for postmenopausal women have varied widely over the last several decades. The 1990s showed a dramatic decline in prescribing and only recently are prescription rates increasing again. Use of HRT is first line for women suffering from the symptoms of menopause. For a certain population of postmenopausal women, HRT is recommended for prevention of fracture. More consideration is being given to patient risk factors, side effects, and formulations available...
August 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28509626/custom-compounded-bioidentical-hormone-therapy-why-so-popular-despite-potential-harm-the-case-against-routine-use
#16
M L'Hermite
Wide rejection of conventional hormone therapy (HT) after the initial publication of the Women's Health Initiative (WHI) led to unjustified use of custom-compounded bioidentical hormones. In the USA, it became an unregulated drug manufacturer industry in disguise, without proper control and making false claims and misleading advertisements. Manufacturing quality is not ensured. Unspecific harm from compounding has occurred on a large scale, such as deaths from infected products and end-stage renal failure plus carcinoma due to confusion between different Chinese herbs...
June 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28496491/the-effects-of-transdermal-estrogen-delivery-on-bone-mineral-density-in-postmenopausal-women-a-meta-analysis
#17
Fatemeh Abdi, Hamid Mobedi, Farhad Bayat, Nariman Mosaffa, Mahrokh Dolatian, Fahimeh Ramezani Tehrani
Due to its minimal systematic adverse effects, transdermal estrogen is widely used for the prevention of osteoporosis in postmenopausal women. The present meta-analysis aimed to clarify the effects of transdermal estrogen on bone mineral density (BMD) of postmenopausal women. Studies were identified by searching electronic databases including Cochrane Library, MEDLINE, Embase , and CINAHL databases, and also the Sciences Citation Index. Systematic review of articles was published between January 1989 to February 2016...
2017: Iranian Journal of Pharmaceutical Research: IJPR
https://www.readbyqxmd.com/read/28426619/committee-opinion-no-698-hormone-therapy-in-primary-ovarian-insufficiency
#18
(no author information available yet)
Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28426614/committee-opinion-no-698-summary-hormone-therapy-in-primary-ovarian-insufficiency
#19
(no author information available yet)
Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment...
May 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28364870/plasma-orexin-a-levels-in-recently-menopausal-women-during-and-3-years-following-use-of-hormone-therapy
#20
RANDOMIZED CONTROLLED TRIAL
Dahima Cintron, John P Beckman, Kent R Bailey, Brian D Lahr, Muthuvel Jayachandran, Virginia M Miller
OBJECTIVE: Alterations in sleep quality and metabolism during menopause are improved by menopausal hormone therapy (MHT). The mechanisms mediating these effects remain unclear. Orexin A (OxA) is a neuro-peptide that regulates sleep/wakefulness, food intake and metabolism. This study examined changes in plasma OxA levels during and after treatment in women from the Kronos Early Estrogen Prevention Study (KEEPS). METHODS: KEEPS randomized women within three years of menopause to: oral conjugated equine estrogen (o-CEE, 0...
May 2017: Maturitas
keyword
keyword
95818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"